文献速递乳腺癌

HER2低表达与HER2-0乳腺癌患者新辅助化疗后的病理完全缓解率和无病生存率

Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers.
PubMed 文献 · Eur J Cancer · 2022-09-28

研究基于Institut Paoli-Calmettes数据库2005年1月至2021年6月接受新辅助化疗的1111例乳腺癌患者,比较HER2低表达与HER2-0肿瘤的病理完全缓解(pCR)和无病生存(DFS)。HER2低表达发生率为41%,与激素受体(HR)阳性相关;全人群中HER2低表达pCR率低于HER2-0(23% vs 30%,p=0.013),但多因素分析后关联消失;HR阳性患者中HER2低表达pCR率更低(10% vs 16%,p=0.046),HR阴性患者中无差异;DFS与HER2状态无相关性。

要点

  • HER2低表达占新辅助化疗乳腺癌患者的41%,且与HR阳性相关。
  • 全人群中HER2低表达pCR率低于HER2-0(23% vs 30%),但多因素分析后无显著关联。
  • HR阳性患者中HER2低表达pCR率低于HER2-0(10% vs 16%),HR阴性患者中无差异。

核心结论

  • HER2低表达与HR阳性相关;HER2状态不影响HR阴性患者的pCR,但HER2低表达与HR阳性患者较低的pCR率相关。

研究设计与样本

  • 基于Institut Paoli-Calmettes数据库的队列研究,纳入2005年1月至2021年6月接受新辅助化疗的可评估乳腺癌患者1111例。
  • HER2低表达定义为HER2免疫组化(IHC)评分1+或2+且荧光原位杂交(FISH)阴性,HER2-0定义为IHC评分0。
  • 比较两队列的临床病理特征、pCR(定义为[ypT0/ypTis]且[pN0sn或ypN0])和无病生存(DFS)率。

主要发现

  • HER2低表达发生率为41%,其中HR阳性占63%、HR阴性占37%(p < 0.001)。
  • 全人群中HER2低表达pCR率为23%,HER2-0为30%(p = 0.013),但该关联在多因素分析中消失。
  • HR阳性患者中HER2低表达pCR率为10%,HER2-0为16%(p = 0.046),多因素分析中该结果维持。
  • HR阴性患者中HER2低表达pCR率为46%,HER2-0为42%,无显著差异。
  • DFS与HER2状态之间无相关性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Half of HER2-negative breast cancers (BC) show HER2-low expression. The strong efficacy of recent anti-HER2 antibody-drug conjugates (ADC) in HER2-low tumours has risen the interest of HER2-low as a proper BC subtype. Chemosensitivity and prognosis of this subtype are not clear when compared to HER2-0 tumours. We investigated the pathological complete response (pCR) and disease-free survival (DFS) rates in BC patients receiving neoadjuvant chemotherapy for HER2-low or HER2-0 tumours. METHODS: Data were collected from the Institut Paoli-Calmettes database. HER2-low tumours were defined by HER2 IHC score of 1+ or 2+ with negative FISH, and HER2-0 by IHC score of 0. Clinicopathological characteristics, pCR (defined as [ypT0/ypTis] and [pN0sn or ypN0]) and DFS rates were compared between the two cohorts. RESULTS: From Jan/2005 to Jun/2021, 1111 patients receiving neoadjuvant chemotherapy were evaluable. The incidence of HER2-low was 41%, including 63% of hormone receptor (HR)-positive and 37% of HR-negative tumours (p < 0.001). In the whole population, the pCR rate was lower in HER2-low (23%) versus HER2-0 (30%) tumours (p = 0.013), but this association was lost in multivariate analysis. In HR-positive patients, HER2-low negatively impacted pCR rates when compared to HER2-0 (10% vs. 16%, p = 0.046), but not in HR-negatives (46% vs. 42%), and this result was maintained in multivariate analysis. No correlation existed between DFS and HER2-status. CONCLUSION: HER2-low is associated with HR positivity. HER2 status did not impact pCR in HR-negative patients, whereas HER2-low was associated with lower pCR rate in HR-positive patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. de Nonneville A, Houvenaeghel G, Cohen M, et al. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers. Eur J Cancer. 2022. PMID: 36257173. doi:10.1016/j.ejca.2022.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。